ロード中...
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma
BACKGROUND: IDH1mutated glioblastoma (GB) has a better prognosis than IDH1wildtype GB. However, it remains unknown whether patients (pts)with IDH1mutated GB ha ve a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate on clinical trials for recurrence. DESIGN/METHODS: R...
保存先:
| 出版年: | J Neurooncol |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5021066/ https://ncbi.nlm.nih.gov/pubmed/27270908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2157-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|